Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Publication

Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administrationin patients with advanced gastrointestinal carcinomas

V. Moreno, et al. ESMO 2022 – Download the Poster

Published 17 April 2022
Categorized as 2022, Publication, TG6002

Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF

JB Marchand et al. AACR 2022 Abstract available on the AACR website – Download the poster

Published 11 April 2022
Categorized as 2022, BT-001, Publication

Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients

MS Block et al.AACR 2022Read the abstract here – Download the poster herePoster Presentation

Published 8 April 2022
Categorized as 2022, Myvac, Publication, TG4050

Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

P. Cassier et al. ESMO 2021 Download the poster here Poster Presentation

Published 16 September 2021
Categorized as -others, 2021, Publication, TG6002

3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses

Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation

Published 1 July 2021
Categorized as -others, -others, 2021, BT-001, Publication, TG6002

Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas

K. Bendjama et al. AACR 2021 Read the abstract here – Download the poster here Poster Presentation

Published 9 April 2021
Categorized as -others, 2021, Invir.IO, Publication, TG6002

Immunocompetent cancer-on-chip models to assess immuno-oncology therapy

Tengku Ibrahim Maulana, et al. Adv Drug Deliv Rev., March 30 2021 – Read the article Publication

Published 30 March 2021
Categorized as -others, 2021, Publication

Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs

Jérémy Béguin, et al. Sci Rep., January 26 2021 – Read the article Publication

Published 26 January 2021
Categorized as -others, 2021, Publication, TG6002

Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC

Adrian von Witzleben, et al. Front Oncol., January 26 2021 – Read the article Publication

Published 26 January 2021
Categorized as -others, 2021, Publication, TG4001

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

Franck Gallardo, et al. Biomedicines, November 26 2020 – Read the article Publication

Published 26 November 2020
Categorized as -others, 2020, Invir.IO, Publication

Posts pagination

Newer posts Page 1 … Page 5 … Page 13 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu